Although the ability to detect SVs in our pipeline depends on the location of breakpoints and gene baits (see “Methods”), this approach led to the identification of an inversion event, resulting in a RUNX1-ETS2 fusion in a patient with myeloid BC, which was confirmed by performing reverse transcription PCR (RT-PCR) and Sanger sequencing (Fig. 2b and Supplementary Fig. 3). This evidence concerns the gene RUNX1 and breast cancer.